Business Wire

CA-CEPTON-TECHNOLOGIES

9.9.2019 15:02:04 CEST | Business Wire | Press release

Share
CNL Software Announce Technology Partnership with Cepton LiDAR at the GSX

CNL Software, a world leader in Physical Security Information Management (PSIM) software, is pleased to announce a technology partnership with Cepton Technologies, a developer of industry-leading 3D sensing solutions, at the GSX in Chicago. The partnership will drive the automation of threat detection, tracking and escalation in real time using the latest PSIM, LiDAR and video assessment technologies.

Cepton Technologies’ Helius™ system is a smart lidar network utilizing edge computing to provide real-time detection, tracking and classification. It can seamlessly track an object from sensor to sensor, providing 3D data on location, dimensions, and velocity, while maintaining the same identification of the object.

By connecting multiple laser-powered sensors, it offers comprehensive coverage of a given area as well as high resolution imaging of objects. Sensors can be clustered as needed but act as one to maximize the simplicity of use and integration. With the in-built software in the hardware unit, Helius is browser-based and can launch on computers and mobile devices for instant monitoring and configuration, without installations of additional software. Furthermore, being edge-based, Helius processes data locally and outputs low-bandwidth data to the central server.

“CNL Software is committed to working with new and innovative technologies that will give our customers improved security and greater efficiency. Cepton’s lidar sensor technology brings the technological leaps that have taken place in autonomous vehicles to the security industry, especially in the government and critical infrastructure markets where we are experiencing growing demand for the integration of multiple different security system and sensor technologies,” comments Keith Bloodworth, CEO, CNL Software. “When integrated with IPSecurityCenterTM , Helius further enhances the industry’s most comprehensive PSIM system solution, providing users with access to more of the tools they need to quickly see, understand, assess and properly resolve perimeter security and surveillance incidents, consistently.”

Neil Huntingdon, Cepton’s VP of Business Development, added: “Our technology’s ability to detect and track events in traditionally difficult environments combined with IPSecurityCenter’s ability to correlate this data with data from other security systems and sensors and provide decision support is a powerful proposition. We’re really excited to be partnering with CNL Software to bring this game changing solution to the government, critical infrastructure, safe city and transportation markets, in particular. It will unlock that ‘missing layer’ by filling the medium-range sensor gap and improve it with the capability to classify objects as well as behaviors.”

For more information about CNL Software’s PSIM solution and deployments, please visit Booth #1713 at the GSX in Chicago on September 10– 12 2019. To book a demonstration, please email marketing@cnlsoftware.com

About Cepton Technologies, Inc.

Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.

Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.

Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines. For more information, visit: http://www.cepton.com/ .

Cepton will also have a separate booth at stand 1894, next to the bistro.

About CNL Software

More than a decade ago, we set out to create a PSIM platform to transform the way organizations manage their physical security. Today, IPSecurityCenter is trusted by the best-informed security operations in national security, critical infrastructure and large enterprises around the world. For more information, visit www.cnlsoftware.com .

Physical Security Information Management (PSIM) LinkedIn Group

The PSIM Group brings together users, integrators, consultants and manufacturers of Physical Security Information Management software to share ideas, thought leadership, tips, tricks, future developments and more! Please follow visit https://www.linkedin.com/groups/2162880

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye